Survival estimates of a prognostic classification depended more on year of treatment than on imputation of missing values.

[1]  Richard Sylvester,et al.  International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers , 1997 .

[2]  R. Motzer,et al.  Risk assessment for metastatic testis cancer. , 1998, The Urologic clinics of North America.

[3]  J. Schafer.  Multiple imputation: a primer , 1999, Statistical methods in medical research.

[4]  F. Harrell,et al.  Regression models for prognostic prediction: advantages, problems, and suggested solutions. , 1985, Cancer treatment reports.

[5]  Sylvia Richardson,et al.  Markov Chain Monte Carlo in Practice , 1997 .

[6]  D. Rubin.  Multiple imputation for nonresponse in surveys , 1989 .

[7]  J. Richie,et al.  The National Cancer Data Base report on patterns of care for testicular carcinoma, 1985–1996 , 1999, Cancer.

[8]  D B Rubin,et al.  Multiple imputation in health-care databases: an overview and some applications. , 1991, Statistics in medicine.

[9]  P. Wilkinson,et al.  High-dose chemotherapy and autologous haematopoietic support in poor risk non-seminomatous germ-cell tumours: an effective first-line therapy with minimal toxicity. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  C. Bokemeyer,et al.  First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial , 2003, British Journal of Cancer.

[11]  F. Harrell,et al.  Regression modelling strategies for improved prognostic prediction. , 1984, Statistics in medicine.

[12]  J. Tabernero,et al.  BOMP/EPI intensive alternating chemotherapy for IGCCC poor-prognosis germ-cell tumors: the Spanish Germ-Cell Cancer Group experience (GG) , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  R. Stahel,et al.  Risk-Adapted Chemotherapy of Germ Cell Tumors with Carboplatin, Etoposide and Bleomycin for Low-Risk and Cisplatin, Etoposide and Ifosfamide for High-Risk Patients , 2000, Oncology.

[14]  Douglas G Altman,et al.  Developing a prognostic model in the presence of missing data: an ovarian cancer case study. , 2003, Journal of clinical epidemiology.

[15]  H S Koops,et al.  Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era , 2001, Cancer.

[16]  R. Motzer,et al.  Testicular germ-cell cancer. , 1997, The New England journal of medicine.

[17]  H. Boshuizen,et al.  Multiple imputation of missing blood pressure covariates in survival analysis. , 1999, Statistics in medicine.

[18]  S. Kaye,et al.  Bleomycin, vincristine, cisplatin/bleomycin, etoposide, cisplatin chemotherapy: an alternating, dose intense regimen producing promising results in untreated patients with intermediate or poor prognosis malignant germ-cell tumours , 2004, British Journal of Cancer.

[19]  Adriana Pérez,et al.  Use of the mean, hot deck and multiple imputation techniques to predict outcome in intensive care unit patients in Colombia , 2002, Statistics in medicine.

[20]  Andrew Briggs,et al.  Missing... presumed at random: cost-analysis of incomplete data. , 2003, Health economics.

[21]  E W Steyerberg,et al.  Survival of patients with nonseminomatous germ cell cancer: a review of the IGCC classification by Cox regression and recursive partitioning , 2004, British Journal of Cancer.

[22]  M. Climent,et al.  Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG). , 2002, European urology.